Granulocyte Colony-Stimulating Factor
"Granulocyte Colony-Stimulating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Below are MeSH descriptors whose meaning is more general than "Granulocyte Colony-Stimulating Factor".
Below are MeSH descriptors whose meaning is more specific than "Granulocyte Colony-Stimulating Factor".
This graph shows the total number of publications written about "Granulocyte Colony-Stimulating Factor" by people in this website by year, and whether "Granulocyte Colony-Stimulating Factor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Granulocyte Colony-Stimulating Factor" by people in Profiles.
Acetylation impacts Fli-1-driven regulation of granulocyte colony stimulating factor. Eur J Immunol. 2016 10; 46(10):2322-2332.
Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. J Immunotoxicol. 2016 11; 13(6):784-792.
Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor ? in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo. J Immunol. 2015 Jun 01; 194(11):5211-22.
G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol. 2013 Oct 01; 6:75.
Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. J Natl Cancer Inst. 2013 Aug 07; 105(15):1072-3.
Colony-stimulating factors for febrile neutropenia. N Engl J Med. 2013 07 18; 369(3):286.
Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar 21; 368(12):1131-9.
Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. Am Heart J. 2012 Nov; 164(5):689-697.e3.
Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences. Am J Manag Care. 2012 05 01; 18(5):e168-72.
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. 2012 Nov; 47(11):1403-8.